Novo Nordisk has intensified its campaign against copycat versions of its blockbuster obesity and diabetes treatments, filing 14 additional U.S. lawsuits this week against telehealth providers and compounding pharmacies that sell non-FDA-approved forms of semaglutide, the active ingredient in Wegovy and Ozempic. The Danish group says the products are unsafe and misbranded, and it is seeking injunctions and damages to halt their distribution. The fresh complaints, which name firms such as Hims & Hers, Fella Health and Mochi Health, expand Novo’s litigation in the United States to more than 130 active cases. Although the FDA lifted its shortage designation for Wegovy in May, the company estimates more than one million U.S. patients are still using compounded GLP-1 drugs sold at steep discounts. The legal escalation comes as competition from Eli Lilly’s rival treatment Zepbound and persistent use of compounded GLP-1s weigh on Novo’s outlook. The company last week trimmed its 2025 sales-growth forecast to 8–14% and warned price erosion could accelerate in the second half of the year. In results published on Wednesday, Novo reported second-quarter revenue of DKK 76.9 billion (about US$11.9 billion), a 13% rise that marked its slowest pace in four years. Sales of Wegovy grew 67% to DKK 19.5 billion, yet investors remain concerned about copycat pressure; shares have fallen roughly 30% since the profit warning. Management said further cost-cutting, including potential layoffs and R&D project terminations, is under review as incoming chief executive Maziar Mike Doustdar prepares to take charge on 7 August.